Amring Appoints Dr. Eric D. Donnenfeld to its U.S. Medical Advisory Board Chair
Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., announced the appointment of Dr. Eric D. Donnenfeld, a distinguished figure in ophthalmology, as the Chair of its U.S. Medical Advisory Board (MAB). This strategic decision comes as the company gears up to introduce LACRIFILL® canalicular gel, a novel therapy for Dry Eye Disease, to the U.S. market.
The U.S. MAB, under Dr. Donnenfeld's leadership, boasts a team of esteemed experts, including Dr. Richard Lindstrom (Minnesota), Dr. Vance Thompson (South Dakota), Dr. Preeya Gupta (North Carolina), Dr. Paul Karpecki (Kentucky), Dr. Lisa Nijm (Illinois), and Dr. Selina McGee (Oklahoma). Their collective expertise is set to play a pivotal role in the launch and success of LACRIFILL®, a novel FDA-cleared hyaluronic acid derivative designed to temporarily alleviate tear drainage by occluding the canalicular system.
Philip Gioia, President of the U.S. team at Nordic Pharma, expressed his enthusiasm about Dr. Donnenfeld's leadership, highlighting his over 30 years of clinical experience as an internationally recognized authority in refractive, cornea, and cataract surgery. Gioia emphasized, "Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market. With over 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery he brings invaluable insights for developing physician-led strategies, enhancing the patient experience and phase IV study initiatives."
Jai G. Parekh, MD, MBA, Chief Commercial Officer of Nordic Pharma Eye Care U.S., lauded Dr. Donnenfeld's contributions to eye care, stating, "I have been fortunate to work closely with Eric over the last 20 years. He is an outstanding clinician and surgeon with a pulse on new technology. Eric is responsible for many of the most successful launches in eye care and our team looks forward to collaborating with him. He will be instrumental in guiding us during LACRIFILL's introduction to eye care providers and patients."
Dr. Donnenfeld shared his excitement about the role and the innovative potential of LACRIFILL®, remarking, "I’m excited to be part of the LACRIFILL launch as this technology is disruptive and will change the way we practice ophthalmology and optometry. It’s an honor to be working with Nordic Pharma’s leadership and our highly respected Medical Advisory Board to bring this novel dry eye disease therapy to ophthalmologists and optometrists across the U.S. and then around the world."
In addition to Dr. Donnenfeld's appointment, Amring has been invited to join the American-European Congress of Ophthalmic Surgery (AECOS) and will prominently feature at the AECOS Winter Symposium this week. Dr. Vance Thompson is set to present on the benefits of LACRIFILL®, alongside discussing select pre-order opportunities and leading the Dry Eye Disease Update session.
